The START Center for Cancer Research dosed the first patient in Moderna’s Phase 1 trial of mRNA-4106, a multivalent ...

The FDA granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv), the first targeted therapy for previously ...

Lumipulse G pTau217/β-Amyloid 1-42—for the diagnosis of Alzheimer’s disease. It demonstrated 91.7% sensitivity and 97.3% ...

The European Commission has approved a perioperative regimen of Bristol Myers Squibb’s immunotherapy drug Opdivo® (nivolumab) ...

ONCOLife is delighted to announce that Dr İlkiz Er Dağ, MD, MBA, has joined the company as Project Director for Oncology ...

The V Foundation for Cancer Research, a top-rated cancer charity, announced an exciting partnership with Cancer Vaccine ...

Leucid Bio has dosed the first patient in its Phase 1 AERIAL trial of LEU011, an NKG2D-targeting CAR-T therapy for solid ...

New 10-year results from the APHINITY trial show that adding pertuzumab (Perjeta®) to trastuzumab (Herceptin®) and ...

CytomX's CX-2051, a PROBODY® EpCAM-targeted antibody-drug conjugate (ADC), showed a 28% confirmed response rate and 5.8-month ...

Johnson & Johnson’s Oncology Care Index reveals 73% of oncologists see a gap between new cancer treatments and clinical ...

Phase III POTOMAC trial showed that adding Durvalumab (Imfinzi) to BCG induction and maintenance therapy significantly ...

For the first time, the FDA completed a generative AI-assisted scientific review pilot, cutting review tasks from days to ...